21 February 2014- WALTZ CoCr Coronary Stent System ("WALTZ"), independently developed by Shanghai MicroPort Medical (Group) Co., Ltd, gained CE certificate.
WALTZ CoCr Coronary Stent System is the platform for FireBird2 Rapamycin eluting coronary stent system and is designed for the treatment of ischemic heart disease. It consists of a L605 cobalt-based alloy stent and a delivery system. Mr. Zhirong Tang, Vice President of Coronary R&D, stated, "With competitive operational performance, WALTZ should be an excellent option for patients who are suitable for bare metal stent."
The CE approval provides preconditions for WALTZ to penetrate most international markets.
This website may store cookies on your browser. Cookies are mostly used to make the website work as you expect it to. No cookie will directly identify you, but it can give you a more personalized browsing experience.
MicroPort respects your privacy rights, so you can block some types of cookies. Technically non-essential cookies and tracking mechanisms, that enable us to provide you with customized offers (marketing cookies), are only used if you have given prior consent to such use.
By clicking “Save”, only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings.